Bach-Yen Nguyen - Concepedia

Concepedia

Author

Bach-Yen Nguyen

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

Bach-Yen Nguyen, Bach-Yen T Nguyen, Bach-Yen T. Nguyen, Randi Leavitt

21

Publications

4.4K

Citations

17

H-Index

23

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Emory University University of North Carolina at Chapel Hill Universitat de Barcelona Sorbonne Université

BN

About

Bach-Yen Nguyen is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, hiv, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	2.6K
2	Epidemiology	5	5	1K
3	Hepatology	4	4	431
4	Public Health	1	1	25
5	Pharmacology	1	1	10

Bach-Yen Nguyen

×

19

Publications

4.4K

Citations

17

H-Index

	Year	Citations
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection Roy T. Steigbigel, David A. Cooper, Princy Kumar, New England Journal of Medicine	2008	683
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study David Roth, David R. Nelson, Annette Bruchfeld, The Lancet Hepatic DisordersHepatitis CViral HepatitisChronic Kidney DiseaseCombination Phase 3	2015	663
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Jeffrey L. Lennox, Edwin DeJesus, Adriano Lazzarin, The Lancet Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral ResponseAntiviral Therapy	2009	619
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial Beatriz Grinsztejn, Bach-Yen Nguyen, Christine Katlama, The Lancet Multidrug-resistant VirusTreatment And PreventionAntiviral Drug DevelopmentAntiviral TherapyVirology	2007	566
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection David A. Cooper, Roy T. Steigbigel, José M. Gatell, New England Journal of Medicine	2008	505
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial Jürgen K. Rockstroh, Mark Nelson, Christine Katlama, The Lancet HIV Open-label TrialHepatologyHepatitis CHepatitis C VirusViral Hepatitis	2015	306
Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses Jeffrey L. Lennox, Edwin DeJesus, Daniel S Berger, JAIDS Journal of Acquired Immune Deficiency Syndromes	2010	227
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial Joseph J. Eron, Jürgen K. Rockstroh, Jacques Reynes, The Lancet Infectious Diseases Treatment And PreventionHuman RetrovirusClinical TrialsAntiviral TherapyUntreated Patients	2011	190
Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK Jürgen K. Rockstroh, Jeffrey L. Lennox, Edwin DeJesus, Clinical Infectious Diseases	2011	164
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials Joseph J. Eron, David A. Cooper, Roy T. Steigbigel, The Lancet Infectious Diseases Benchmrk StudiesTreatment And PreventionAntiviral Drug DevelopmentClinical TrialsPlacebo-controlled Trials	2013	127

Page 1